Stocks
Intellia Therapeutics (NTLA) EBITDA margin US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -789.5% | -864.5% | -1 396% | -905.3% | -586.3% | -601.7% | ||
| Changes by years, y/y, % | -565pp | -75pp | -531pp | +490pp | +319pp | +21.2% | |||
Intellia Therapeutics. EBITDA margin, %
Intellia Therapeutics. EBITDA margin, changes, pp
Intellia Therapeutics (NTLA) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA margin, % | ? | -711.5% | -693.4% | -699.4% | -414.5% | -624.9% | -601.7% | |
| Changes by years, y/y, % | -326pp | +1 268pp | +861pp | +625pp | +87pp | |||
| Changes by quarters, q/q, % | +328pp | +18pp | -6pp | +285pp | -210pp | |||
